Pharmaceuticals News and Research

RSS

Novel approach to pain therapy paves way for lower dosage painkillers

For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.

11 Jun 2013

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

GE Healthcare announced today its plans to invest $2 billion over the next five years to accelerate the development of innovative software for healthcare systems and applications.

11 Jun 2013

Study explores various strategies, suggests cost-effective options for HIV testing in India

In India most people who are HIV positive don't know it, yet testing and treatment are relatively cheap and available. It would therefore meet international standards of cost-effectiveness - and save millions of lives for decades - to test every person in the billion-plus population every five years according to a new study published in the journal PLoS One.

11 Jun 2013

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets. The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

10 Jun 2013

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced 10 new or updated software packages to help customers harness the power of its new-generation liquid chromatography-mass spectrometry (LC-MS) instruments and turn data into knowledge in a wide range of discovery and quantitation experiments.

From Thermo Fisher Scientific Inc. 10 Jun 2013

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system, combining its three mass analyzers –quadrupole, Orbitrap and linear ion trap – in a novel “Tribrid” architecture that offers unprecedented depth of analysis of complex biological samples.

From Thermo Fisher Scientific Inc. 10 Jun 2013

African medicinal plants contain chemicals that may help stop spread of cancer cells

African medicinal plants contain chemicals that may be able to stop the spread of cancer cells. This is the conclusion of researchers following laboratory experiments conducted at Johannes Gutenberg University Mainz (JGU).

10 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines.

10 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation.

10 Jun 2013

Nation's leading experts join forces to accelerate effective treatments for brain tumors

The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.

10 Jun 2013

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published.

10 Jun 2013

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.

7 Jun 2013

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

The European Technology Platform on Nanomedicine and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

7 Jun 2013

Aflibercept drug used for AMD shows no added benefit over current standard therapy

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy.

7 Jun 2013

Researchers define nine molecular hallmarks of aging, debunk myths related to antioxidants

For some species, living twice as long in good health depends on no more than a few genes. When this fact was revealed by studies on worms three decades ago, it ushered in a golden age of ageing studies that has delivered numerous results, but also sown some confusion.

7 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Anthrax vaccines have a prominent place in the history of medicine. This goes back to, Pasteur, who while everybody associates with the milk treatment process, also worked on rabies and Anthrax vaccines in cattle.

6 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Pharmaceuticals News and Research

Novel approach to pain therapy paves way for lower dosage painkillers

GE Healthcare plans to invest $2 billion to develop innovative software for healthcare systems

Study explores various strategies, suggests cost-effective options for HIV testing in India

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

African medicinal plants contain chemicals that may help stop spread of cancer cells

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

NanoViricides files Orphan Drug application with FDA for DengueCide

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Nation's leading experts join forces to accelerate effective treatments for brain tumors

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

Aflibercept drug used for AMD shows no added benefit over current standard therapy

Researchers define nine molecular hallmarks of aging, debunk myths related to antioxidants

Diagnoplex secures 1.3 million Swiss francs from financing round

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence